Peptinov is a biotechonology company based in Cochin Hospital (Paris, France) and founded by Prof. Jean-François Zagury to develop innovative peptide-based immunotherapies to treat chronic inflammatory diseases. The primary targets of Peptinov are cytokines. Cytokines are major messenger proteins of the immune system and their overproduction is involved in the pathogenesis of several chronic inflammatory diseases (such as rheumatoid arthritis, osteoarthritis, systemic sclerosis or Horton's disease). Peptinov’s strategy is to induce the production of anti-cytokine antibodies directly by the organism of the patient, through immunizations against carefully selected, highly immunogenic peptide sequences. Peptinov’s high potential R&D platform uses the tools of bioinformatics and molecular modelling to design these peptide sequences. This platform is potentially applicable to any crystallized protein and can quickly generate peptide candidates. Peptinov’s value proposition is built on its unique capability to develop anti-cytokine and anti-self proteins products in the current pharmaceutical markets. Peptinov's most advanced product targets IL-6, a central pro-inflammatory cytokine involved in the pathogenesis of several diseases. Peptinov's anti-IL-6 immunotherapy will enter clinical development in Q1 2019. To fund this clinical development, Peptinov launches a crowdfunding campaign with its partner Happy Capital: https://youtu.be/LsYDtiblSNk http://www.bordeaux.tv/happy-capital-peptinov/